Diabetes Care Devices Market - Growth, Trends, and Forecasts (2020 - 2025)

The Diabetes Care Devices Market is segmented by Management Devices (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, Jet Injectors), and Monitoring Devices (Self-monitoring Blood Glucose, Continuous Glucose Monitoring), and Geography.

  • ABOUT THIS REPORT
    • Market Snapshot
    • Market Overview
    • Scope of the Report
    • Key Market Trends
    • Competitive Landscape
    • Major Players
  • TABLE OF CONTENTS

Market Snapshot

Study Period:

2012-2025

Base Year:

2019

Fastest Growing Market:

North America

Largest Market:

North America

CAGR:

6.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The diabetes care devices market is expected to register a CAGR greater than 6.8% during the forecast period (2020 - 2025). North America is anticipated to dominate the market during the forecast period, owing to the rising prevalence of obesity in the region. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advances give many conveniences in measuring blood glucose levels. One such advancement in monitoring the blood glucose levels is the continuous glucose monitoring devices.

Scope of the Report

The study provides a detailed analysis of the diabetes care devices market globally and includes market share, size, forecast, and industry overview. The report also offers a country-wise analysis.

Monitoring Devices (Value and Volume, 2012 - 2025)
Self-monitoring Blood Glucose Devices
Glucometer Devices
Test Strips
Lancets
Continuous Glucose Monitoring
Sensors
Durables
Management Devices (Value and Volume, 2012 - 2025)
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Insulin Cartridges
Disposable Pens
Jet Injectors
Geography
North America
United States (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Canada (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Rest of North America (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Europe
France (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Germany (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Italy (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Spain (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
United Kingdom (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Russia (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Rest of Europe (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Latin America
Mexico (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Brazil (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Rest of Latin America (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Asia-Pacific
Japan (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
South Korea (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
China (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
India (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Australia (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Vietnam (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Malaysia (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Indonesia (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Philippines (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Thailand (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Rest of Asia-Pacific (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Middle-East and Africa
Saudi Arabia (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Iran (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Egypt (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Oman (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
South Africa (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
Rest of Middle-East and Africa (Value and Volume, 2012 - 2025)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Rising Prevalence of Diabetes

The Diabetes Care Device market reached USD 69.7 billion in 2019 and is anticipated to register a CAGR of 4.6% during the forecast period (2020 - 2025). Approximately 4.2 million adults aged 20–79 years are estimated to die as a result of diabetes and its complications in 2019. This is equivalent to one death every eight seconds. Diabetes is estimated to be associated with 11.3% of global deaths from all causes among people in this age group. Almost half (46.2%) of deaths associated with diabetes among the 20–79 years age group is in people under the age of 60 years – the working-age group. Globally, there are more deaths associated with diabetes in women (2.3 million) than in men (1.9 million).

To understand key trends, Download Sample Report

North America to Dominate the Monitoring Devices Segment

The factors attributing to the North American market growth is the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles. Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, a growing obese population, and government initiatives of raising awareness regarding diabetic care. According to IDF, in 2019, USD 324.5 billion was spent on diabetes in the region, which is 42.7% of the total global health expenditure on diabetes. In North America, USD 294.6 billion was spent in the United States of America alone. The mean annual expenditure per person with diabetes was highest in the United States of America (USD 9,506), followed by Canada (USD 4,397).

To understand geography trends, Download Sample Report.

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of a few strategic outcomes include: 

  • In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for Guardian(TM) Connect continuous glucose monitoring (CGM) system, for people with diabetes aged between 14-75 years. 
  • In October 2019, U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients, ages two years and up.

Major Players

  1. Dexcom
  2. Medtronic
  3. F. Hoffmann-La Roche AG
  4. Novo Nordisk
  5. Omnipod

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 Monitoring Devices (Value and Volume, 2012 - 2025)

      1. 5.1.1 Self-monitoring Blood Glucose Devices

        1. 5.1.1.1 Glucometer Devices

        2. 5.1.1.2 Test Strips

        3. 5.1.1.3 Lancets

      2. 5.1.2 Continuous Glucose Monitoring

        1. 5.1.2.1 Sensors

        2. 5.1.2.2 Durables

    2. 5.2 Management Devices (Value and Volume, 2012 - 2025)

      1. 5.2.1 Insulin Pump

        1. 5.2.1.1 Insulin Pump Device

        2. 5.2.1.2 Insulin Pump Reservoir

        3. 5.2.1.3 Infusion Set

      2. 5.2.2 Insulin Syringes

      3. 5.2.3 Insulin Cartridges

      4. 5.2.4 Disposable Pens

      5. 5.2.5 Jet Injectors

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States (Value and Volume, 2012 - 2025)

          1. 5.3.1.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.1.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        2. 5.3.1.2 Canada (Value and Volume, 2012 - 2025)

          1. 5.3.1.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.1.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        3. 5.3.1.3 Rest of North America (Value and Volume, 2012 - 2025)

          1. 5.3.1.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.1.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

      2. 5.3.2 Europe

        1. 5.3.2.1 France (Value and Volume, 2012 - 2025)

          1. 5.3.2.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        2. 5.3.2.2 Germany (Value and Volume, 2012 - 2025)

          1. 5.3.2.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        3. 5.3.2.3 Italy (Value and Volume, 2012 - 2025)

          1. 5.3.2.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        4. 5.3.2.4 Spain (Value and Volume, 2012 - 2025)

          1. 5.3.2.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        5. 5.3.2.5 United Kingdom (Value and Volume, 2012 - 2025)

          1. 5.3.2.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        6. 5.3.2.6 Russia (Value and Volume, 2012 - 2025)

          1. 5.3.2.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        7. 5.3.2.7 Rest of Europe (Value and Volume, 2012 - 2025)

          1. 5.3.2.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.2.7.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

      3. 5.3.3 Latin America

        1. 5.3.3.1 Mexico (Value and Volume, 2012 - 2025)

          1. 5.3.3.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.3.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        2. 5.3.3.2 Brazil (Value and Volume, 2012 - 2025)

          1. 5.3.3.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.3.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        3. 5.3.3.3 Rest of Latin America (Value and Volume, 2012 - 2025)

          1. 5.3.3.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.3.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

      4. 5.3.4 Asia-Pacific

        1. 5.3.4.1 Japan (Value and Volume, 2012 - 2025)

          1. 5.3.4.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        2. 5.3.4.2 South Korea (Value and Volume, 2012 - 2025)

          1. 5.3.4.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        3. 5.3.4.3 China (Value and Volume, 2012 - 2025)

          1. 5.3.4.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        4. 5.3.4.4 India (Value and Volume, 2012 - 2025)

          1. 5.3.4.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        5. 5.3.4.5 Australia (Value and Volume, 2012 - 2025)

          1. 5.3.4.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        6. 5.3.4.6 Vietnam (Value and Volume, 2012 - 2025)

          1. 5.3.4.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        7. 5.3.4.7 Malaysia (Value and Volume, 2012 - 2025)

          1. 5.3.4.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.7.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        8. 5.3.4.8 Indonesia (Value and Volume, 2012 - 2025)

          1. 5.3.4.8.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.8.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        9. 5.3.4.9 Philippines (Value and Volume, 2012 - 2025)

          1. 5.3.4.9.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.9.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        10. 5.3.4.10 Thailand (Value and Volume, 2012 - 2025)

          1. 5.3.4.10.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.10.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        11. 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2025)

          1. 5.3.4.11.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.4.11.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

      5. 5.3.5 Middle-East and Africa

        1. 5.3.5.1 Saudi Arabia (Value and Volume, 2012 - 2025)

          1. 5.3.5.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        2. 5.3.5.2 Iran (Value and Volume, 2012 - 2025)

          1. 5.3.5.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        3. 5.3.5.3 Egypt (Value and Volume, 2012 - 2025)

          1. 5.3.5.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        4. 5.3.5.4 Oman (Value and Volume, 2012 - 2025)

          1. 5.3.5.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        5. 5.3.5.5 South Africa (Value and Volume, 2012 - 2025)

          1. 5.3.5.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

        6. 5.3.5.6 Rest of Middle-East and Africa (Value and Volume, 2012 - 2025)

          1. 5.3.5.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)

          2. 5.3.5.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2012-2025)

    2. 6.2 Type-2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Abbott

      2. 7.1.2 F. Hoffmann-La Roche AG

      3. 7.1.3 Johnson & Johnson

      4. 7.1.4 Dexcom

      5. 7.1.5 Medtronic

      6. 7.1.6 Novo Nordisk

      7. 7.1.7 Ascensia Diabetes Care

      8. 7.1.8 AgaMatrix

      9. 7.1.9 Bionime Corporation

      10. 7.1.10 Omnipod

      11. 7.1.11 Medisana

      12. 7.1.12 Trivida

      13. 7.1.13 Rossmax International Ltd.

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports

LINKS

CONTACT

Location Logo

5th Floor, Brigade Towers,

Financial District, Gachibowli,

Hyderabad - 500032,

India

Phone Logo

+1 617-765-2493

Email Logo[email protected]

JOIN US

We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination.

Interested? Please email us

[email protected]

© 2020. All Rights Reserved to Mordor Intelligence.